https://www.selleckchem.com/products/azd8186.html
icalTrials.gov, identifier NCT04237493. www.ClinicalTrials.gov, identifier NCT04237493.Background and Purpose Natalizumab is a highly efficacious disease-modifying therapy for relapsing-remitting multiple sclerosis (MS). Data on the efficacy and safety profile of natalizumab in Asian patients with MS are limited. This study assessed the efficacy and safety of natalizumab in Korean patients with MS in a real-world setting. Methods This study enrolled consecutive Korean patients with active relapsing-remitting MS who were treated with nat
Beğen
Yorum Yap
Paylaş
